Vertex Pharmaceuticals, Inc.

Catalyst Biosciences, Inc.

Grant E Blouse

Tom Knudsen

Eric Steven Furfine

Jeffrey Charles Way

Matthew John Traylor

Howard Levy

Christine René Schar

Agnieszka Jendroszek

Arzu Sandikci

Jim Mcguire

Shyam Rajan Iyer

Jan Kristian Jensen

Natacha Le Moan

Emil Oldenburg

Brajesh Kumar

Provided herein are Complement Factor I (CFI) variants that exhibit at least one improved characteristic relative to a wild type CFI. CFI variants of the disclosure can exhibit tunable specificity and activity. Also included are CFI-containing fusion constructs comprising at least one domain of CFI, for example, wild type full length CFI fused to human serum albumin. Also included are methods of making and using such CFI variants and fusion constructs. The CFI variants and fusion constructs provided herein may be useful for treating a disease or condition associated with dysregulation of the complement system or a deficiency of CFI.

Complement factor I-related compositions and methods

Provided herein are modified FVII polypetides, and modified FVIIa polypeptides, and methods of treatment of acute and episodic bleeding with modified FactorVIIa polypeptides. To effect treatment and use, in some embodiments, the modified polypeptides are subcutaneously administered to provide on-demand treatment. In some embodiments, the on-demand treatment is provided in a multiple dosing regimen over a twenty-four hour period. The subcutaneous administration of the modified polypeptides of the disclosure exhibit increased coagulant activity, potency, bioavailablilty and prolonged duration.

Modified factor VII polypeptides for subcutaneous administration and on-demand treatment

Growing community of inventors

Burlingame, CA, United States of America

Grant E Blouse